RNA Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board

TransCode Therapeutics has strategically strengthened its scientific leadership by appointing Dr. Phillip D. Zamore, a distinguished expert in RNA interference (RNAi), to its Scientific Advisory Board. Dr. Zamore, who currently serves as Chair of the RNA Therapeutics Institute at UMass Chan Medical School, brings decades of groundbreaking research and expertise in RNA biology to the clinical-stage oncology company.

The appointment represents a significant opportunity for TransCode, which is focused on developing innovative RNA therapeutic approaches to treat metastatic cancer. Dr. Zamore's extensive background, including his co-founding of Alnylam Pharmaceuticals and his election to the National Academy of Sciences, suggests potential for substantial scientific insights and strategic guidance.

As a pioneer in RNAi research, Dr. Zamore's contributions could be particularly valuable to TransCode's lead therapeutic candidate, TTX-MC138, which targets microRNA-10b in metastatic tumors. His expertise may help refine the company's proprietary TTX nanoparticle platform and enhance its approach to delivering RNA therapeutics.

TransCode's leadership views this appointment as a strategic enhancement to their cancer therapy programs. Dr. Zamore's deep understanding of gene silencing mechanisms and RNA biology could potentially accelerate the development of novel genetic targets for cancer treatment.

The addition of such a prominent scientific figure to the advisory board signals TransCode's commitment to cutting-edge research and innovative therapeutic strategies in the ongoing battle against metastatic cancer.